# Michael J. Overman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-j-overman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,299 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 80 |
| i10-index | 300 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5003827387 |
| ORCID iD | https://orcid.org/0000-0001-5377-135X |
| Works | 1,074 |

## Researcher papers

- [Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study](https://scholariq.org/papers/nivolumab-in-patients-with-metastatic-dna-mismatch-repair-deficient-or/)
- [Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer](https://scholariq.org/papers/durable-clinical-benefit-with-nivolumab-plus-ipilimumab-in-dna-mismatch-repair/)
- [Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/colon-cancer-version-2-2021-nccn-clinical-practice-guidelines-in-oncology/)
- [Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy](https://scholariq.org/papers/improved-survival-in-metastatic-colorectal-cancer-is-associated-with-adoption-of/)
- [Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/rectal-cancer-version-2-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018](https://scholariq.org/papers/disparity-of-race-reporting-and-representation-in-clinical-trials-leading-to/)
- [NCCN Guidelines Insights: Rectal Cancer, Version 6.2020](https://scholariq.org/papers/nccn-guidelines-insights-rectal-cancer-version-6-2020/)
- [Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance](https://scholariq.org/papers/phase-ii-trial-of-infusional-fluorouracil-irinotecan-and-bevacizumab-for/)
- [Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes](https://scholariq.org/papers/classifying-colorectal-cancer-by-tumor-location-rather-than-sidedness-highlights/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.